Expert consensus on the clinical application of the markers of hepatitis B virus.
10.3760/cma.j.cn501113-20230314-00113
- Collective Name:Cooperative Group of Basic Research and Experimental Diagnosis of Liver Diseases, Chinese Society of Hepatology, Chinese Medical Association
- Publication Type:Journal Article
- Keywords:
Biomarker;
Chronic hepatitis B;
Diagnosis;
Treatment
- MeSH:
Humans;
Hepatitis B virus;
Hepatitis B, Chronic/drug therapy*;
Consensus;
Antiviral Agents/therapeutic use*;
Biomarkers;
Hepatitis B/drug therapy*
- From:
Chinese Journal of Hepatology
2023;31(4):389-400
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus biomarkers are mainly used in clinical practice to diagnose infection, monitor disease progression, evaluate response to chronic hepatitis B treatment, and evaluate the efficacy of novel antiviral drugs in clinical trials. In combination with the recent research progress of antiviral therapy for chronic hepatitis B and the actual needs of clinical diagnosis and treatment, the expert consensus was formulated by the Cooperative Group of Basic Research and Experimental Diagnosis of Liver Diseases, Chinese Society of Hepatology, Chinese Medical Association. It summarized the evidence and recommended the key points for the clinical application of classic and novel hepatitis B virus related biomarkers in order to guide the standardized and reasonable clinical application for these biomarkers.
